155 related articles for article (PubMed ID: 32096651)
1. A cell-based assay for the detection of neutralizing antibodies against alemtuzumab.
Ali L; Saxena G; Jones M; Leisegang GR; Gammon L; Gnanapavan S; Giovannoni G; Schmierer K; Baker D; Kang AS
Biotechniques; 2020 Apr; 68(4):185-190. PubMed ID: 32096651
[No Abstract] [Full Text] [Related]
2. The Irony of Humanization: Alemtuzumab, the First, But One of the Most Immunogenic, Humanized Monoclonal Antibodies.
Baker D; Ali L; Saxena G; Pryce G; Jones M; Schmierer K; Giovannoni G; Gnanapavan S; Munger KC; Samkoff L; Goodman A; Kang AS
Front Immunol; 2020; 11():124. PubMed ID: 32117274
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis.
Li Z; Richards S; Surks HK; Jacobs A; Panzara MA
Clin Exp Immunol; 2018 Dec; 194(3):295-314. PubMed ID: 30144037
[TBL] [Abstract][Full Text] [Related]
4. Alemtuzumab depletion failure can occur in multiple sclerosis.
Dubuisson N; Baker D; Kang AS; Pryce G; Marta M; Visser LH; Hofmann WE; Gnanapavan S; Giovannoni G; Schmierer K
Immunology; 2018 Jun; 154(2):253-260. PubMed ID: 29247512
[TBL] [Abstract][Full Text] [Related]
5. Detecting and predicting neutralization of alemtuzumab responses in MS.
Saxena G; Moore JM; Jones M; Pryce G; Ali L; Leisegang GR; Vijay V; Loveless S; Robertson NP; Schmierer K; Giovannoni G; Gnananpavan S; Baker D; Tallantyre EC; Kang AS
Neurol Neuroimmunol Neuroinflamm; 2020 Jul; 7(4):. PubMed ID: 32499328
[TBL] [Abstract][Full Text] [Related]
6. Targeting CD52 does not affect murine neuron and microglia function.
Ellwardt E; Vogelaar CF; Maldet C; Schmaul S; Bittner S; Luchtman D
Eur J Pharmacol; 2020 Mar; 871():172923. PubMed ID: 31962100
[TBL] [Abstract][Full Text] [Related]
7. Different fermentation processes produced variants of an anti-CD52 monoclonal antibody that have divergent in vitro and in vivo characteristics.
Zhuang C; Zheng C; Chen Y; Huang Z; Wang Y; Fu Q; Zeng C; Wu T; Yang L; Qi N
Appl Microbiol Biotechnol; 2017 Aug; 101(15):5997-6006. PubMed ID: 28512676
[TBL] [Abstract][Full Text] [Related]
8. Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis.
von Kutzleben S; Pryce G; Giovannoni G; Baker D
Immunology; 2017 Apr; 150(4):444-455. PubMed ID: 27925187
[TBL] [Abstract][Full Text] [Related]
9. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.
Hu Y; Turner MJ; Shields J; Gale MS; Hutto E; Roberts BL; Siders WM; Kaplan JM
Immunology; 2009 Oct; 128(2):260-70. PubMed ID: 19740383
[TBL] [Abstract][Full Text] [Related]
10. Ocrelizumab for Post-Alemtuzumab Paradoxical Disease Activity in Highly Active Multiple Sclerosis.
Adamec I; Habek M
Clin Neuropharmacol; 2022 Sep-Oct 01; 45(5):139-141. PubMed ID: 36093911
[TBL] [Abstract][Full Text] [Related]
11. Impact of an anti-infective screening and monitoring protocol together with infectious disease consultation in preventing infective adverse events in patients treated with anti-CD20/CD52 agents for multiple sclerosis.
Zappulo E; Buonomo AR; Moccia M; Pinchera B; Villari R; Petracca M; Lanzillo R; Scotto R; Carotenuto A; Viceconte G; Schiano Moriello N; Bruno L; Gentile I; Brescia Morra V
Mult Scler Relat Disord; 2022 Jul; 63():103814. PubMed ID: 35487032
[TBL] [Abstract][Full Text] [Related]
12. Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models.
Siders WM; Shields J; Garron C; Hu Y; Boutin P; Shankara S; Weber W; Roberts B; Kaplan JM
Leuk Lymphoma; 2010 Jul; 51(7):1293-304. PubMed ID: 20377308
[TBL] [Abstract][Full Text] [Related]
13. Alemtuzumab for the treatment of multiple sclerosis.
Evan JR; Bozkurt SB; Thomas NC; Bagnato F
Expert Opin Biol Ther; 2018 Mar; 18(3):323-334. PubMed ID: 29309202
[TBL] [Abstract][Full Text] [Related]
14. Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab.
Baker D; Herrod SS; Alvarez-Gonzalez C; Giovannoni G; Schmierer K
JAMA Neurol; 2017 Aug; 74(8):961-969. PubMed ID: 28604916
[TBL] [Abstract][Full Text] [Related]
15. CD52-Negative NK Cells Are Abundant in the Liver and Less Susceptible to Alemtuzumab Treatment.
Hotta R; Ohira M; Matsuura T; Muraoka I; Tryphonopoulos P; Fan J; Tekin A; Selvaggi G; Levi D; Ruiz P; Ricordi C; Vianna R; Ohdan H; Waldmann H; Tzakis AG; Nishida S
PLoS One; 2016; 11(8):e0161618. PubMed ID: 27560943
[TBL] [Abstract][Full Text] [Related]
16. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis.
Zhang X; Tao Y; Chopra M; Ahn M; Marcus KL; Choudhary N; Zhu H; Markovic-Plese S
J Immunol; 2013 Dec; 191(12):5867-74. PubMed ID: 24198283
[TBL] [Abstract][Full Text] [Related]
17. Immune Regulatory Cell Bias Following Alemtuzumab Treatment in Relapsing-Remitting Multiple Sclerosis.
Kashani N; Kelland EE; Vajdi B; Anderson LM; Gilmore W; Lund BT
Front Immunol; 2021; 12():706278. PubMed ID: 34777337
[TBL] [Abstract][Full Text] [Related]
18. The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis.
Rolla S; Maglione A; De Mercanti SF; Clerico M
Cells; 2020 Jun; 9(6):. PubMed ID: 32503344
[TBL] [Abstract][Full Text] [Related]
19. Anti-CD52 antibody treatment depletes B cell aggregates in the central nervous system in a mouse model of multiple sclerosis.
Simon M; Ipek R; Homola GA; Rovituso DM; Schampel A; Kleinschnitz C; Kuerten S
J Neuroinflammation; 2018 Aug; 15(1):225. PubMed ID: 30098594
[TBL] [Abstract][Full Text] [Related]
20. Cytomegalovirus primary infection in a patient with multiple sclerosis treated with alemtuzumab.
Aguirre C; Meca-Lallana V; Sánchez P; Vivancos J
Mult Scler Relat Disord; 2019 Oct; 35():270-271. PubMed ID: 31442904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
